Jacqueline Corrigan-Curay, the acting director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER), announced her retirement effective July 2025 amid a wave of senior leadership departures at the agency. Following her departure, the FDA appointed George Francis Tidmarsh, M.D., Ph.D., a Stanford faculty member and biotechnology veteran with over 30 years of experience in biotechnology, clinical medicine, and regulatory science, as the new director of CDER. Tidmarsh has a background in oncology and pediatrics and has led multiple biotech companies. In addition to his role as CDER director, Tidmarsh was named acting director of the FDA's Center for Biologics Evaluation and Research (CBER) after the abrupt resignation of Vinay Prasad. Scott Steele and Brittany Goldberg were appointed as deputy directors of CBER to support the transition.